Electra Therapeutics, Inc. (NASDAQ:ETRA – Get Free Report) Director Carl Gordon bought 1,333,333 shares of the business’s stock in a transaction on Monday, September 21st. The stock was purchased at an average cost of $15.00 per share, with a total value of $19,999,995.00. Following the purchase, the director owned 5,126,891 shares of the company’s stock, valued at $76,903,365. This represents a 35.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Electra Therapeutics Trading Down 7.0%
NASDAQ ETRA traded down $0.95 on Wednesday, reaching $12.67. 874,135 shares of the company’s stock traded hands, compared to its average volume of 708,715. Electra Therapeutics, Inc. has a 12 month low of $12.50 and a 12 month high of $15.50.
Featured Stories
- Five stocks we like better than Electra Therapeutics
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Electra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
